ArticleScientific reports2025
Profile of the BREATHE cohort for risk-based breast screening in Singapore.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Building a Precision Health Ecosystem: Singapore's Approach to Innovation through the Clinical Implementation Pilots.NPJ genomic medicine · 2026Review
- Breast Cancer Screening Knowledge and Sentiments in Singaporean Women: Mixed Methods Study Using Topic Modeling, Sentiment Analysis, and Structured Questionnaire Data.Journal of medical Internet research · 2026Article
- Article
Corrections and comments
- Erratum issued
Authors and funding
24 authors.
Funding
Abstract
The BREAst screening Tailored for HEr (BREATHE) study was established to pilot a personalised, risk-based breast cancer screening programme for a multi-ethnic Asian population. Between October 2021 and December 2023, 4592 women aged 35-59 were enrolled (73% response rate). Follow-up from February 2022 to June 2024 included 4112 participants (8.6% loss to follow-up). Data collected encompassed demographics, lifestyle factors, reproductive risks, breast cancer awareness, screening behaviours, programme satisfaction, mammography outcomes (density and recall status), and genotype data. Above-average breast cancer risk increased with age: 2% in women aged 35-39, 31% in 40-49, and 42% in 50-59. Findings suggests that women valued the knowledge of their breast cancer risk and were motivated to attend mammography. The BREATHE study confirms the feasibility and acceptability of a personalised risk-based screening programme in a multi-ethnic Asian population, highlighting the value of tailored protocols to improve early detection and outcomes. Further details are available in the study protocol and online at https://blog.nus.edu.sg/breathe/ .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.